Amin Announces Phase 3 MARINE Trial Data to be Presented in May at the National Lipid Association 2011 Annual Scientific Sessions

Amarin Corporation plc AMRN today announced that data from the MARINE trial, a pivotal Phase 3 study investigating AMR101 as a treatment for very high triglycerides, will be presented at the National Lipid Association 2011 Annual Scientific Sessions at the Sheraton New York Hotel and Towers in New York City on May 19-22, 2011. The MARINE trial results will be presented in an abstract titled "AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients With Very High Triglycerides Without Raising LDL-C: the MARINE Study" by Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center, and principal investigator of the study. As reported in November 2010, the MARINE study met its primary endpoint of percent change in triglyceride (TG) levels from baseline to week 12, for both the 4 gram and 2 gram dose groups of AMR101. Additionally, the MARINE study demonstrated no statistically significant increase in LDL cholesterol and a safety profile similar to placebo.